Vera Therapeutics [VERA] vs Celcuity [CELC] Detailed Stock Comparison
Vera Therapeutics
NASDAQ
Loading...
Celcuity
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 15 vital metrics comparison: Vera Therapeutics wins in 4 metrics, Celcuity wins in 8 metrics, with 3 ties. Celcuity appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Vera Therapeutics | Celcuity | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -10.57 | -15.98 | Celcuity |
| Price-to-Book Ratio | 3.92 | 43.33 | Vera Therapeutics |
| Debt-to-Equity Ratio | 16.56 | 224.03 | Vera Therapeutics |
| PEG Ratio | -0.11 | -0.24 | Celcuity |
| EV/EBITDA | -5.79 | -13.84 | Celcuity |
| Profit Margin (TTM) | 0.00% | 0.00% | Tie |
| Operating Margin (TTM) | 0.00% | 0.00% | Tie |
| Return on Equity | -54.84% | -134.54% | Vera Therapeutics |
| Return on Assets (TTM) | -30.24% | -38.49% | Vera Therapeutics |
| Free Cash Flow (TTM) | $-135.65M | $-83.72M | Celcuity |
| 1-Year Return | -28.53% | 228.59% | Celcuity |
| Enterprise Value | $1.37B | $2.03B | Celcuity |
| Revenue per Share (TTM) | $0 | $0 | Tie |
| Earnings per Share (Diluted) | $-3.68 | $-3.39 | Celcuity |
| Beta (Stock Volatility) | 1.16 | 0.73 | Celcuity |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Vera Therapeutics vs Celcuity Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Vera Therapeutics | 1.39% | 8.27% | 29.10% | 23.42% | 23.74% | -30.83% |
| Celcuity | 9.29% | -4.85% | -7.76% | 278.99% | 427.99% | 276.39% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Vera Therapeutics | -28.53% | 46.24% | 153.83% | 153.83% | 153.83% | 153.83% |
| Celcuity | 228.59% | 392.23% | 755.02% | 262.58% | 262.58% | 262.58% |
News Based Sentiment: Vera Therapeutics vs Celcuity
Vera Therapeutics
News based Sentiment: POSITIVE
The combination of a new institutional investment from Perigon Wealth Management and a five-day stock gain streak signals a positive shift for Vera Therapeutics. While not a transformative event, it suggests increasing investor confidence and potential for future growth, making it a noteworthy development for investors.
Celcuity
News based Sentiment: POSITIVE
October was a significant month for Celcuity, highlighted by the FDA acceptance of its NDA for gedatolisib, a key regulatory milestone. While options trading indicated some short-term bearish sentiment, the stock price rebounded and analyst ratings remain positive, suggesting overall positive momentum for the company.
Performance & Financial Health Analysis: Vera Therapeutics vs Celcuity
| Metric | VERA | CELC |
|---|---|---|
| Market Information | ||
| Market Cap | $1.91B | $1.97B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 1,631,290 | 852,180 |
| 90 Day Avg. Volume | 1,793,945 | 886,213 |
| Last Close | $29.19 | $49.42 |
| 52 Week Range | $18.53 - $51.61 | $7.57 - $63.06 |
| % from 52W High | -43.44% | -21.63% |
| All-Time High | $51.61 (Nov 11, 2024) | $63.06 (Sep 09, 2025) |
| % from All-Time High | -43.44% | -21.63% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | N/A |
| Quarterly Earnings Growth | N/A | N/A |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.00% |
| Operating Margin (TTM) | 0.00% | 0.00% |
| Return on Equity (TTM) | -0.55% | -1.35% |
| Debt to Equity (MRQ) | 16.56 | 224.03 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $7.34 | $1.14 |
| Cash per Share (MRQ) | $8.72 | $3.97 |
| Operating Cash Flow (TTM) | $-185,271,008 | $-120,396,744 |
| Levered Free Cash Flow (TTM) | $-111,946,496 | $-73,714,896 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Vera Therapeutics vs Celcuity
| Metric | VERA | CELC |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -10.57 | -15.98 |
| Forward P/E | -9.25 | -15.44 |
| PEG Ratio | -0.11 | -0.24 |
| Price to Sales (TTM) | N/A | N/A |
| Price to Book (MRQ) | 3.92 | 43.33 |
| Market Capitalization | ||
| Market Capitalization | $1.91B | $1.97B |
| Enterprise Value | $1.37B | $2.03B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | N/A |
| Enterprise to EBITDA | -5.79 | -13.84 |
| Risk & Other Metrics | ||
| Beta | 1.16 | 0.73 |
| Book Value per Share (MRQ) | $7.34 | $1.14 |
Financial Statements Comparison: Vera Therapeutics vs Celcuity
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | VERA | CELC |
|---|---|---|
| Revenue/Sales | $0 | $0 |
| Cost of Goods Sold | N/A | N/A |
| Gross Profit | N/A | N/A |
| Research & Development | $41.28M | $32.23M |
| Operating Income (EBIT) | $-57.19M | $-36.13M |
| EBITDA | $-49.82M | $-33.78M |
| Pre-Tax Income | $-51.69M | $-37.00M |
| Income Tax | N/A | $0 |
| Net Income (Profit) | $-51.69M | $-37.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | VERA | CELC |
|---|---|---|
| Cash & Equivalents | $55.09M | $16.48M |
| Total Current Assets | $606.08M | $217.60M |
| Total Current Liabilities | $21.89M | $32.92M |
| Long-Term Debt | $53.27M | $98.54M |
| Total Shareholders Equity | $535.00M | $86.67M |
| Retained Earnings | $-512.94M | $-308.85M |
| Property, Plant & Equipment | $1.06M | $530,000 |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | VERA | CELC |
|---|---|---|
| Operating Cash Flow | $-41.22M | $-36.49M |
| Capital Expenditures | $-187,000 | $-60,000 |
| Free Cash Flow | $-54.59M | $-35.91M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | VERA | CELC |
|---|---|---|
| Shares Short | 9.36M | 5.87M |
| Short Ratio | 4.91 | 6.41 |
| Short % of Float | 0.17% | 0.16% |
| Average Daily Volume (10 Day) | 1,631,290 | 852,180 |
| Average Daily Volume (90 Day) | 1,793,945 | 886,213 |
| Shares Outstanding | 63.56M | 37.14M |
| Float Shares | 42.92M | 18.69M |
| % Held by Insiders | 0.04% | 0.12% |
| % Held by Institutions | 1.10% | 0.84% |
Dividend Analysis & Yield Comparison: Vera Therapeutics vs Celcuity
| Metric | VERA | CELC |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |